Helsinn Therapeutics (US) Inc.
1160 US Highway 22
About Helsinn Therapeutics (US) Inc.Helsinn is a privately owned, self-financing pharmaceutical group with headquarters in Lugano, Switzerland and subsidiaries in Ireland and the USA. The Helsinn Group has been built on the basis of a licensing of pharmaceuticals, with the recent addition of medical devices in therapeutic niche areas. Helsinn is an important player in Cancer Supportive Care and sells its products through unique business model that is focused on the in- and out- distributors in 87 countries worldwide. Helsinn Therapeutics (U.S.), Inc. was established in January, 2009 and is currently developing clinical and preclinical stage ghrelin receptor agonists and antagonists in cancer and gastrointestinal supportive care. The company’s vision is to become a leading specialty company focused on supportive care with direct sales in the U.S. market.
12 articles with Helsinn Therapeutics (US) Inc.
The FDA approves Truseltiq for patients with previously-treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance.
Helsinn Group announces agreement to acquire worldwide rights to Valchlor/Ledaga, an approved and marketed alkylating agent for topical treatment of mycosis fungoides type cutaneous T-cell lymphoma
Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma, a rare type of skin cancer.
Helsinn Therapeutics (US) Inc. Signs Co-Promotion Agreement For Cancer Therapeutic Zykadia In The U.S.
Helsinn Therapeutics (US) Inc. And PatientsLikeMe Announce Results Of NSCLC Patient Survey On Weight Loss
Helsinn Therapeutics (US) Inc. And Eisai Inc. Announce Revised U.S. Collaboration For CINV Franchise
Helsinn Release: Data Presented At The International Society Of Paediatric Oncology (SIOP) Congress Show Palonosetron Is A Valuable Option For Treating Pediatric Patients Receiving Moderately To Highly Emetogenic Chemotherapy
Helsinn Therapeutics (US) Inc. Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Helsinn Therapeutics (US) Inc. Initiates Global Pivotal Phase III Clinical Program to Evaluate Anamorelin in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Helsinn Healthcare SA Announces the Acquisition of Sapphire Therapeutics, Inc. to Establish Helsinn Therapeutics (US) Inc.